Indication: Low-Grade Glioma (LGG)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Sub-indication: Low-Grade Glioma (LGG)
Study Type: Drug Study
Principal Investigator: Ashok Raj, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Children's Oncology Group (COG)
Learn more at ClinicalTrials.gov
Email for more information: NCRI-Cancer@NortonHealthcare.org